• Happy Holidays from Cafepharma! To allow its staff to spend holiday time with their families, the Cafepharma Message Boards will be switched to read-only from 6:00 PM Eastern time on Tuesday, December 24 until 10:00 PM Eastern time on Wednesday, December 25. During this time, all posts will be available for view. However, no one will be able to make new posts during this time.


allergan

  1. Allergan BDM 2 Facial Aesthetics Pay

    Coming from different specialty with very high base ranges. Wanted to know if there’s negotiation room for starting base? I’ve heard it’s less than 100k?! I realize ICP may be large, but that base seems crazy low. Thanks
    • anonymous
    • Thread
    • abbvie aesthetics botox allergan botox
    • Replies: 1
    • Forum: Allergan

  2. Allergan legacy to Abbvie legacy

    Can anyone on the Abbvie side explain the Abbvie code system for sales? I’ve yet to get a straight answer from company…
    • Sowega
    • Thread
    • abbvie allergan
    • Replies: 3
    • Forum: AbbVie

  3. AbbVie might buy Allergan today

    News reports are emerging that AbbVIe might acquire Allergan today to combine forces. Deal not officially announced yet. Source.
    • anonymous
    • Thread
    • abbvie allergan
    • Replies: 0
    • Forum: Allergan

  4. NASH

    Nonalcoholic steatohepatitis (NASH) liver fibrosis is the new golden goose in the biotech space. More than 40 companies are taking part in clinical trials to bring the first NASH drug to market. Very few of them are close to seeing some success. NASH’s market value is set to increase to $21.5...

  5. Key promoted brands drove Allergan to growth in Q3

    Botox Therapeutic and Cosmetic, Juvederm, and Vraylar remained the main growth drivers of Allergan, which reported better than expected third quarter results. The pharma company posted a 3% decline in revenues to $3.91 billion due to a loss of exclusivity on some brands. Non-GAAP revenue rose...
    • anonymous
    • Thread
    • allergan
    • Replies: 3
    • Forum: Allergan

  6. Celgene Q2 earnings - no further price hike in products this year

    Celgene's second quarter results beat estimates and the company lifted 2018 outlook. Celgene will not be increasing the price of its products this year. https://news.alphastreet.com/celgene-q2-2018-earnings/
    • anonymous
    • Thread
    • alexion allergan celgene donald trump drug price eli lilly gilead novartis pfizer sanofi
    • Replies: 1
    • Forum: Celgene

  7. Allergan to sell women’s health and infectious disease units

    According to the CNBC, Allergan will sell its women’s health and infectious disease businesses and will use the proceeds to pay down debt and buy back shares. The company has been struggling since last year. https://news.alphastreet.com/allergan-to-sell-womens-health-and-infectious-disease-units/
    • anonymous
    • Thread
    • allergan
    • Replies: 15
    • Forum: Allergan

  8. Botox, Juvederm sales lift Allergan in first quarter

    Allergan plc reported a 3% improvement in revenues to $3.7 billion for the first quarter of 2018 compared to the prior year period, driven by a 13% increase in its core business which includes the Botox and Juvederm brands. Net loss for the quarter was $332.5 million or $0.99 per diluted share...
    • anonymous
    • Thread
    • allergan botox earnings
    • Replies: 9
    • Forum: Allergan

  9. Allergan app

    I am obviously outsider here, but I really really need your help. I am a salesperson, and I cannot access the apps that Allergan provide, and I can not get anyone including my boss to help me, and I think that it would help me a lot in mine job in demonstration purposes. So if anyone can provide...

  10. Allergan to pay $700 million to Teva

    Allergan agrees to pay $700 million to Teva in this quarter. Teva discloses this in an SEC filing.
    • anonymous
    • Thread
    • agreement allergan arbitration settlement teva teva pharmaceuticals
    • Replies: 1
    • Forum: Allergan

  11. Will Pfizer again attempt to acquire Allergan?

    When providing the outlook for 2018, Saunders said that Allergan faces LOE losses in 2018. But still it has got good long-term prospects. Saunders says that current stock price doesn't reflect Allergan's true value. Wall Street gives thumbs up to his speech.
    • anonymous
    • Thread
    • acquisition allergan guidance job cuts outlook pfizer teva
    • Replies: 4
    • Forum: Allergan

  12. You are fired - New Year greetings from Allergan

    http://alph.st/p90f71e5 During the earnings call in last November, when an analyst asked whether Allergan will split or sell its businesses, Brent Saunders said "No". He was also saying the company is planning a strategy "... they're difficult decisions, but those are the things that leadership...
    • anonymous
    • Thread
    • allergan job cuts jobs restructuring
    • Replies: 44
    • Forum: Allergan

  13. Sandoz wins the patent case against Allergan

    This is the second patent win for Sandoz in December 2017. Allergan is expected to file for rehearing within 30 days on patent ruling. Earlier in Dec., Sandoz also won a patent case against Amgen.
    • anonymous
    • Thread
    • allergan amgen lawsuit novartis patent sandoz
    • Replies: 0
    • Forum: Novartis

  14. A bad move by Allergan

    I don't know why Allergan is buying this struggling penny stock company. I don't think Allergan can do what Repros couldn’t and deliver the safety data that the FDA is looking for.
    • anonymous
    • Thread
    • acquisition allergan buyout deal repros
    • Replies: 10
    • Forum: Allergan

  15. A wrinkle for Allergan; Botox competitor reports positive data

    Revance Therapeutics reports positive data for RT002. http://alph.st/b96326ac A threat to Allergan's Botox, which accounted for 19% of total revenue in Allergan's recently ended quarter.
    • anonymous
    • Thread
    • allergan botox revance therapeutics
    • Replies: 3
    • Forum: Allergan

  16. Brent Saunders says Allergan stock is undervalued

    Allergan swings to quarterly loss on charges related to Restasis and Teva holding. Given the Federal Court's decision, plans to mitigate the financial impact of generic competition http://alph.st/b68181eb
    • anonymous
    • Thread
    • allergan earnings pfizer restasis shire teva
    • Replies: 1
    • Forum: Allergan

  17. Alternative for Restasis

    Allergan faces another trouble. Imprimis Pharma to produce alternative medicine for Restasis. http://alph.st/p97f8975
    • anonymous
    • Thread
    • allergan imprimis pharma
    • Replies: 4
    • Forum: Allergan

  18. Allergan gets a major blow

    Texas court says Mohawk Tribe patent deal is not legit. "The Court has serious concerns about the legitimacy of the tactic that Allergan and the Tribe have employed," Judge William Bryson said in a memorandum opinion accompanying his decision.
    • anonymous
    • Thread
    • allergan deal patent
    • Replies: 2
    • Forum: Allergan

  19. Settles with Pfizer's subsidiary on Restasis patent

    Allergan reaches a settlement with InnoPharma, a subsidiary of Pfizer on Restasis patent. Out of the four contestants, Mylan, Teva and Akorn are still contesting the patents in the federal court. http://alph.st/b3437240
    • anonymous
    • Thread
    • agreement allergan lawsuit patent pfizer settlement
    • Replies: 2
    • Forum: Allergan

  20. How Brent Saunders will defend Allergan's unfair move?

    Will Congress take any action on the letter from 10 lobbying groups?
    • anonymous
    • Thread
    • allergan deal
    • Replies: 5
    • Forum: Allergan
Top Bottom
Back